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Background: Local control rates in patients with retroperitoneal soft tissue sarcoma (RSTS) remain disappointing
even after gross total resection, mainly because wide margins are not achievable in the majority of patients. In
contrast to extremity sarcoma, postoperative radiation therapy (RT) has shown limited efficacy due to its limitations
in achievable dose and coverage. Although Intraoperative Radiation Therapy (IORT) has been introduced in some
centers to overcome the dose limitations and resulted in increased outcome, local failure rates are still high even if
considerable treatment related toxicity is accepted. As postoperative administration of RT has some general
disadvantages, neoadjuvant approaches could offer benefits in terms of dose escalation, target coverage and
reduction of toxicity, especially if highly conformal techniques like intensity-modulated radiation therapy (IMRT) are
considered.
Methods/design: The trial is a prospective, one armed, single center phase I/II study investigating a combination
of neoadjuvant dose-escalated IMRT (50–56 Gy) followed by surgery and IORT (10–12 Gy) in patients with at least
marginally resectable RSTS. The primary objective is the local control rate after five years. Secondary endpoints are
progression-free and overall survival, acute and late toxicity, surgical resectability and patterns of failure. The aim of
accrual is 37 patients in the per-protocol population.
Discussion: The present study evaluates combined neoadjuvant dose-escalated IMRT followed by surgery and IORT
concerning its value for improved local control without markedly increased toxicity.
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
written informed consent missing written informed consent
histologically confirmed,
primary or locally recurrent
soft tissue sarcoma of the
retroperitoneal space
missing histological conformation of
soft tissue sarcoma
judged as at least
marginally resectable
Desmoid Tumors (aggressive fibromatosis),
Gastrointestinal Stroma Tumors (GIST)
absence of
distant metastases
judged as gross incomplete
or not resectable
tumor size≥ 5 cm incomplete staging
presence of distant metastases
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The retroperitoneal space is the site of origin for about
15% of soft tissue sarcomas [1]. Complete excision with
wide margins represents the mainstay of treatment,
however even gross total resections are possible only in
about 50% of the patients [2,3] because of the often lo-
cally advanced tumors which frequently already involve
vital structures at time of diagnosis [3]. Even if gross
total resection is possible, margins are typically narrow
because of the normal tissue limitations [3,4] conse-
quently the local failure rate after surgery alone remains
high [5-7]. In accordance to extremity soft tissue sarco-
mas (STS), where randomized trials have demonstrated
improved local control by the addition of radiation [8,9],
considerable interest has been paid in the use of post-
operative radiation approaches in retroperitoneal STS
also. However, the efficacy of postoperative external
beam irradiation (EBRT) is limited because of the inabi-
lity to deliver adequate doses in account for the tole-
rance limits of stomach, small bowel, kidney, liver and
spinal cord [10], especially when conventional radiation
techniques are used. Because of the known dose-
relationship resulting in improved local control rates if
doses beyond 55–60 Gy are used [11,12], some centers
including ours investigated the use of an intraoperative
radiation therapy (IORT) boost to overcome the dose
limits of postoperative EBRT [3,10,13-15]. The only ran-
domized trial reported so far [13] found a significantly
improved local control rate of 60% using a combination
of 20 Gy IORT and 35–40 Gy EBRT compared to 20%
control with 50–55 Gy postoperative EBRT alone. The
reduction of local failures was even accompanied by a
lower rate of gastrointestinal toxicities with the use of
IORT, but neuropathy emerged as a dose-limiting side
effect. [13]. However, it has been shown, that neurotoxi-
city is hardly increased if the intraoperative dose is limi-
ted to less than 15 Gy [16]. Given the necessity of a
slightly lowered intraoperative dose and the aim of a fur-
ther improvement in local control, it seems reasonable
to investigate an increased EBRT dose component in the
combined treatment approach. Compared to the post-
operative approach, preoperative radiation therapy and
the use of improved irradiation techniques seem
favourable for the following reasons : Preoperative radia-
tion therapy allows for a more precise target volume def-
inition and delineation with smaller safety margins,
reduces toxicity to adjacent organs at risk because of
their displacement through the tumor itself, may lead
to a devitalisation of tumor cells including a down-
sizing effect, and may avoid a treatment delay due to
postoperative complications. Considering improved ir-
radiation techniques, intensity-modulated radiation
therapy (IMRT) has been shown to result in improved
target coverage and reduced dose to adjacent organs atrisk compared to conventional irradiation, as shown in
several diseases including retroperitoneal sarcoma
[17,18], especially if complex shaped target volumes
have to be treated [19]. Further on, IMRT offers the
opportunity to reduce overall treatment time using an
integrated boost concept with simultaneously increased
dose per fraction in parts of the target volume which
are at increased risk for incomplete resection during
planned surgery.
Therefore, the primary aim of this trial is to investigate
the value of dose-escalated preoperative IMRT followed
by surgery with an intraoperative electron boost to reduce
the local recurrence rate without a markedly increased
toxicity. This combination yields total doses which should
be able to control even microscopic residual disease with-
out harm to the adjacent organs at risk.Methods and design
Study design
The trial is designed as a prospective single-center one-
armed phase I/II study to assess the efficacy and safety
of a combination regimen consisting of neoadjuvant
intensity-modulated dose-escalated radiation therapy fol-
lowed by surgery and an intraoperative electron radiation
therapy boost to the tumor bed in patients with gross re-
sectable or borderline resectable soft tissue sarcomas of
the retroperitoneal space.Patient selection and inclusion/exclusion criteria
A minimum of 37 patients fulfilling the inclusion criteria
listed below should be enrolled in this trial. Only
patients meeting all of the inclusion criteria and missing
all of the exclusion criteria (see Table 1) are considered
for admission to the trial. Accrual will be stopped after
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is reached (see statistical considerations).
Trial organization
The study has been designed by the Departments of
Radiation Oncology and General Surgery of the University
of Heidelberg in cooperation with the Departments of
Radiation Oncology, Biostatistics and Medical Physics at
the German Cancer Research Center (DKFZ) Heidelberg.
It is carried out by the Department of Radiation Oncology
at the German Cancer Research Center together with the
Departments of Radiation Oncology and General Surgery
at the University of Heidelberg. The trial is an investigator
initiated trial.
Coordination
The trial is coordinated by the Department of Radiation
Oncology at the German Cancer Research Center
(DKFZ) in cooperation with the Departments of General
Surgery and Radiation Oncology of the University of
Heidelberg. The Departments of Radiation Oncology at
the German Cancer Research Center and at the University
of Heidelberg are responsible for overall trial manage-
ment, database management, quality assurance, reporting
and for the scientific program of all trial related meet-
ings. The trial has been registered at ClinicalTrials.gov
[NCT01566123].
Investigators
Patients will be recruited by the Departments of General
Surgery, Radiation Oncology or Internal Medicine at the
University Hospital of Heidelberg, the Department of
Radiation Oncology at the German Cancer Research
Center or the National Center for Tumor Diseases
(NCT) at the University of Heidelberg. All investigators
are experienced oncologists from the field of radiation
oncology or surgery cooperating in this trial.
Ethical and legal considerations
The study protocol was approved by the independent
ethics committee of the Medical Faculty at the Univer-
sity of Heidelberg. The trial is carried out by adhering to
local legal and regulatory requirements. The study com-
plies with the Declaration of Helsinki 2004, the princi-
ples of Good clinical practice (GCP) and the German
Federal Data Protection Act. Written informed consent
is obtained from each patient before inclusion into the
trial after nature, scope and possible consequences of
participation in the trial have been explained by a
physician.
Study objectives and endpoints
The primary objective is the local control rate after 5 years.
Secondary objectives are progression-free-survival, overallsurvival, acute and late toxicity, resectability and patterns
of recurrence.
Pretreatment evaluation
Initial work up consists of clinical examination, labora-
tory tests including renal and hepatic function, histo-
logical confirmation of diagnosis, CT or MR-imaging of
the abdominal cavity, thoracic CT, bone scan, scintireno-
graphy, evaluation of general ability to receive major sur-
gery and evaluation of resectability.Treatment assignment and schedule
All patients eligible for the trial after pre-treatment
evaluation (see inclusion/exclusion criteria, Table 1) who
gave written informed consent are registered in the
trial and assigned to the same treatment regimen (see
Figure 1). They receive immobilization and treatment plan-
ning examinations for neoadjuvant intensity-modulated
radiation therapy (IMRT) either at the Department
of Radiation Oncology at the German Cancer Research
Center or the University of Heidelberg. Neoadjuvant
intensity-modulated irradiation starts within 6 weeks
after registration and is carried out in 5 fractions per
week for 5–6 weeks using an image guided, stereotactic,
intensity-modulated approach up to a total dose of
50–56 Gy. Reevaluation including restaging and as-
sessment of toxicity takes place within 2 to 4 weeks
after the last fraction. Surgical resection of the tumor
including Intraoperative Radiation Therapy (IORT)
with a single dose of 10–12 Gy is carried out within
6 weeks after the end of neoadjuvant irradiation at the De-
partment Surgery in cooperation with the Department
of Radiation Oncology at the University of Heidelberg.
After postoperative recovery, all patients will be assigned
to regular follow up visits either at the Department of
Radiation Oncology at the German Cancer Research
Center or at the Departments of Surgery or Radiation
Oncology.
Neoadjuvant intensity-modulated radiation therapy
and reevaluation
For external beam radiation therapy, patients are immobi-
lized using a custom-made, individually manufactured body
mask system (Scotch CastTM, 3 M, St. Paul-Minneapolis,
USA) or a vacuum pillow (BlueBagTM, Medical Intelligence,
Schwabmünchen, Germany) combined with a custom-
made individually manufactured head mask system (Scotch
CastTM, 3 M, St. Paul-Minneapolis, USA) mounted to
a stereotactic body frame, resulting in an accuracy of
less than 3.6 mm [20]. For treatment planning, con-
trast enhanced CT as well as MR imaging is per-
formed for optimal target definition. Organs at risk
like small bowel, stomach, liver, kidneys, bladder,
Screening 
Completion of staging 





Neodjuvant IMRT 25-28 Fx 
(start within 6 weeks from registration) 
Reevaluation (CT/MRT)  
(2-4 weeks from the end of neoadjuvant IMRT) 
Surgery + IORT (10-12 Gy)  
(within 6 weeks from the end of neoadjuvant IMRT) 
Follow up 
Figure 1 Flow Chart of the Study. IMRT: Intensity-Modulated
Radiation Therapy, IORT: Intraoperative Radiation Therapy,
Fx: Fractions.
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Gross Tumor Volume (GTV) includes all macroscopically
visible tumor lesions on imaging. The clinical target vo-
lume (CTV) includes the gross tumor volume with a
safety margin of 1.5 cm in all directions. A safety margin
of 5 mm is added to obtain the Planning Target Volume
(PTV). The margins may be reduced with respect to ana-
tomical borders or organs at risk at the discretion of the
investigator. The prescribed dose to the PTV is 45–50 Gy
in single fractions of 1.8-2.0 Gy. The prescribed dose to
the GTV is 50–56 Gy in single fractions of 2.0-2.4 Gy
using an integrated boost concept. The total dose is pre-
scribed to the median of the GTV, while the target
volumes should be surrounded by the corresponding 95%
isodose lines. The generally accepted tolerance doses [21]for the organs at risk are maintained during the ra-
diation therapy planning. Inverse treatment planning is
carried out using the planning systems at the Depart-
ment of Radiation Oncology of the German Cancer Re-
search Center. Treatment is performed using step-and-
shoot intensity modulated radiation therapy with 5 to
13 coplanar 6 MV-beams after stereotactic target point
localisation. Setup correction is done using an image-
guided approach with an In-Room-CT on rails (Siemens
Somatom Emotion, Siemens, Erlangen, Germany) by
comparison of the current CT with the planning CT at
least once a week. Reevaluation including restaging with
abdominal CT or MRI and assessment of toxicity is per-
formed 2 to 4 weeks after the last fraction of neoadju-
vant irradiation.Surgery and intraoperative radiation therapy
Surgery is performed within six weeks after completion
of neoadjuvant irradiation at the Department of General
Surgery of the University of Heidelberg. A gross total re-
section is attempted. An additional intraoperative elec-
tron boost will be performed using a dedicated linear
accelerator inside the operation theatre (Siemens Mevatron,
Siemens, Concord, USA). The target volume of the intrao-
perative boost includes the tumor bed or the high risk
region for positive or close margins as defined by the
treating surgeon and the radiation oncologist together
if the complete tumor bed cannot be covered. Therefore
an applicator of appropriate size is placed inside the ab-
dominal cavity and attached to the table. Uninvolved
radiosensitive tissues are removed from the treatment area
or covered by lead shielding. After alignment with the ac-
celerator, the target volume is irradiated with a single dose
of 10–12 Gy, prescribed to the 90% isodose. The electron
energy is selected according to the tissue depth that has to
be covered in order to encompass the target volume with
the 90% isodose.Follow up
Regular follow up visits start at the day of discharge from
the Department of General Surgery at the University of
Heidelberg and will take place every 3 months after sur-
gery for the first 2 years and every 6 months for three fur-
ther years. They will include clinical and laboratory
examinations, CT or MR-imaging of the abdominal cavity,
thoracic CT (every 6 months in the first two years, every
year thereafter) and assessment of acute and late toxicity
as well as any other necessary examination, test or im-
aging in case of suspicion of local or distant failure at dis-
cretion of the treating physician. All patients will be
followed for 5 years or until death or end of study partici-
pation due to other reasons.
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Full analysis set
The Full analysis Set (FAS) consists of all patients
included in the trial irrespective whether any protocol
violation was present during treatment under study con-
ditions or whether the patient was taken off-study any
time after treatment start, except patients who withdraw
informed consent before the first radiation treatment or
about whom it becomes known that major in-/exclusion
criteria have been violated which would have excluded
them from study participation when known at start of
treatment.Per protocol population
The Per Protocol population consists of all patients
meeting the inclusion criteria and receiving the full
treatment according to this protocol.Assessment of efficiacy
Local control rate after 5 years is the primary endpoint
of the trial. It will be assessed by repeated CT or MR-
imaging during regular follow up. In case of a single sus-
picious locoregional lesion, histological confirmation will
be attempted. Otherwise, new lesions with typical radio-
logical signs and/or clinical behaviour of a local recur-
rence will be counted as local recurrence. In case of
missing surgical resection of the tumor after neoadju-
vant radiotherapy, a local disease progression according
to RECIST criteria (version 1.0) will be counted as a
local recurrence. Special attention should further be
given to avoid that tissue reaction to radiation or surgi-
cal treatment is classified as local recurrence or disease
progression. Variations in post-radiotherapy or post-
surgery imaging may continue for months and may be
accompanied by clinical signs and symptoms. In such
cases, the labelling of the lesion suspicious for recur-
rence or progression must be based on the clinical
follow-up including their developement over time. If the
course of events shows that true recurrence or progres-
sion indeed occurred, the date of the first appearance or
progression of the suspicious lesion is to be considered
as the date of recurrence or progression.
Progression-free survival (PFS) is a secondary endpoint
of the study, determined as the time span from the first
day of radiation therapy until local or distant recurrence
or progression or death due to any cause is found, what-
ever occurred first. Patients alive without progressive dis-
ease at the time of data analysis will be censored at the
time of the most recent follow up. In case of lesions suspi-
cious for distant metastases, histological or cytological
confirmation is attempted. Otherwise, new lesions with
typical radiological signs and/or clinical behaviour of dis-
tant metastases will be counted as progression.Overall survival is a secondary endpoint of the study,
calculated from the first day of radiation treatment until
death of any cause. Patients not reported dead or lost to
follow-up will be censored at the date of the last follow-
up examination.
Assessment of toxicity
Acute radiation toxicity will be assessed according to
Common Terminology Criteria for Adverse Events Ver-
sion 3.0 (CTCAE 3.0) during the time period from the first
day of neoadjuvant radiation treatment until 3 months
after surgery. Late radiation toxicity will be scored accord-
ing to CTCAE 3.0 and RTOG criteria. Toxicity will regu-
larly be evaluated by clinical and laboratory examinations
at least once a week during neoadjuvant external beam ra-
diation therapy and the first follow up visits at discharge
of the Department of General Surgery and after 3 months.
Late toxicity will regularly be scored during every further
regular follow up visit.
Sample size estimation, confirmatory and descriptive
analyses
The primary endpoint of the trial is the local control rate
after five years (LC-5yR). The study is designed to
demonstrate that the combination of neoadjuvant dose-
escalated intensity-modulated radiation therapy with
surgery and intraoperative radiation therapy can improve
the local control rate after five years. Local control rate
after five years in a comparable patient population trea-
ted with standard procedures (surgery followed by adju-
vant three-dimensional conformal radiotherapy) was
estimated to be 50% according to the literature. The
sample size calculation was designed on the assumption
to detect an improvement by 20% in this primary endpoint.
For sample size calculation, the following hypotheses have
been made:
– p0 is the largest LC-5yR which, if true, implies that
the efficacy of the study treatment is too low. In the
present trial P0 has been taken as 50%
– p1 is the lowest LC-5yR which, if true, implies that
the efficacy of the treatment is adequate. In the
present trial p1 has been taken as 70%
– α is the acceptance probability of considering
adequate efficacy of the treatment with a true LC-5yR
equal or lower to p0 (false positive decision). In the
present trial α has been taken as 5%
– β is the acceptance probability of rejecting adequate
efficacy of the study treatment with a true LC-5yR
at least equal to p1 (false negative decision). In the
present trial β has been taken as 20%.
Using the one-sided binomial test (“Exact Test”) with
the given hypotheses, the study requires 37 patients to
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greater or equal to 0.7. If the number of locally con-
trolled patients is ≥24, the hypothesis that LC-5yR is≤
0.5 will be rejected with a target error rate of 0.05. Sam-
ple size calculation and confirmatory analysis are based
on the per protocol population [22].
Secondary endpoints are all of explorative nature and
reported using descriptive analysis methods. Time to
event data (progression free survival, overall survival)
will be evaluated using the Kaplan-Meier-Method.
Safety and discontinuation of treatment
Toxicities are classified by type, grade, duration, onset
and relationship to radiation treatment. Severe acute
gastrointestinal toxicity (≥ grade 3) is the main dose
limiting factor in patients receiving adjuvant three-
dimensional conformal radiation therapy after surgery.
The safety analysis was designed to demonstrate that
the combination of neoadjuvant intensity-modulated
radiation therapy with surgery and intraoperative
radiation therapy will not result in an increased rate
of severe acute gastrointestinal toxicity. The rate of
patients who will suffer from acute severe gastrointes-
tinal toxicity in a comparable patient population trea-
ted with standard procedures (surgery followed by
adjuvant three-dimensional conformal radiotherapy)
was estimated to be 20%.
A toxicity related discontinuation criteria was imple-
mented such that after having recruited about one third
of the total number of patients an increase by 20% of
the onset of severe acute gastrointestinal toxicities (from
20% to 40%) should be detected with a power of 80% at
a level of significance of α= 5% in one interim analysis.
Therefore, an optimal two-stage design [23] was calcu-
lated which suggested to do an interim analysis after
n1 = 15 patients among a total of 43 and to stop for toxi-
city when more than r1 = 5 patients would show severe
gastrointestinal toxicity. Since the calculated sample size
was n = 37, these numbers were adjusted to n1 = 13 and
r1 = 4. Therefore, the study should stop for toxicity after
13 patients if ≥ 5 patients would have developed a severe
acute gastrointestinal toxicity.
Current status
To date 20 patients have been enrolled so far. The
planned safety analysis has taken place after the first
13 patients enrolled on the study had completed
local treatment:
Severe acute gastrointestinal toxicity ≥ grade III was
observed in 1 patient (lymph fistula and duodenal sten-
osis after surgery with the need for parenteral nutrition
until stent placement). Other acute severe toxicities≥
grade III during radiation therapy were found in 1 patient
(leucopenia). Other severe postoperative complicationsdefined by the need for reintervention or intensive care
treatment occurred in 2 of 13 patients (acute renal failure
and sepsis in one and severe wound healing disturbance
in one patient). No fatal toxicities (grade 5) have been
observed so far. As the toxicity related discontinuation cri-
teria (see safety and discontinuation of treatment) was not
reached, the investigators decided to continue with the
study until the planned sample size will be reached.
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